{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:22:19Z","timestamp":1790479339894,"version":"4.1.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The increasing usage of proton pump inhibitors (PPIs) has been reported worldwide, but information on PPI use in East Asia is inadequate. This study aimed to examine the trends in PPI use in Japan, along with the changes in histamine H<jats:sub>2<\/jats:sub> receptor antagonist (H<jats:sub>2<\/jats:sub>RA) use, disease rate of reflux esophagitis, and the prevalence of upper gastrointestinal symptoms. We analyzed 217,712 healthy subjects (127,607 men and 90,105 women; 51.4 \u00b1 9.7 years old) participating in the health check program from 2010 to 2019. Various upper gastrointestinal symptoms were evaluated using the frequency scale for the symptoms of gastroesophageal reflux disease (FSSG) questionnaire. Reflux esophagitis was diagnosed by esophageal erosion using the Los Angeles classification grades A, B, C, and D. From 2010 to 2019, the percentage of PPI users increased markedly from approximately 1.8% to 5.3%, whereas that of H<jats:sub>2<\/jats:sub>RA users decreased gradually from approximately 2.5% to 1.9%. The use of all classical types of PPIs (omeprazole, lansoprazole, rabeprazole, and esomerazole) and a new type of PPI, a potassium-competitive acid blocker (vonoprazan), greatly increased during the 10 years. An upward trend in the prevalence of reflux esophagitis was observed from 2010 to 2015, but not from 2016 to 2019, indicating that the monotonic rising prevalence of reflux disease stopped in the middle of the 2010s in Japan. In contrast, various upper gastrointestinal symptoms significantly improved between 2010 and 2019. All 12 FSSG symptoms of PPI users were significantly worse than those of non-PPI users, suggesting that PPIs still cannot completely control upper gastrointestinal symptoms. In conclusion, this study revealed a significant increase in PPI use and a slight decrease in H<jats:sub>2<\/jats:sub>RA use from 2010 to 2019. Despite a plateau in the prevalence of reflux esophagitis and considerable improvement in various upper gastrointestinal symptoms, PPI use has continued to increase in Japan.<\/jats:p>","DOI":"10.1371\/journal.pone.0270252","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:29:00Z","timestamp":1655486940000},"page":"e0270252","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-9887","authenticated-orcid":true,"given":"Nobutake","family":"Yamamichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3066-9501","authenticated-orcid":true,"given":"Yu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-9189","authenticated-orcid":true,"given":"Chihiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-1140","authenticated-orcid":true,"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"pone.0270252.ref001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2018.08.001","article-title":"Proton pump inhibitors: what the internist needs to know","volume":"103","author":"SJ Spechler","year":"2019","journal-title":"Med Clin North Am"},{"key":"pone.0270252.ref002","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"PO Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"pone.0270252.ref003","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-016-1227-8","article-title":"Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015","volume":"51","author":"K Iwakiri","year":"2016","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","article-title":"Evidence-based clinical practice guidelines for peptic ulcer disease 2020","volume":"56","author":"T Kamada","year":"2021","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/ajg.2016.563","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"112","author":"WD Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"pone.0270252.ref006","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.cgh.2006.09.012","article-title":"Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials","volume":"5","author":"WH Wang","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0270252.ref007","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/ajg.2017.154","article-title":"ACG and CAG clinical guideline: management of dyspepsia","volume":"112","author":"P Moayyedi","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"pone.0270252.ref008","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1136\/gutjnl-2013-305997","article-title":"Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett\u2019s oesophagus: a systematic review and meta-analysis","volume":"63","author":"S Singh","year":"2014","journal-title":"Gut"},{"key":"pone.0270252.ref009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2015.07.041","article-title":"Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients With symptomatic esophageal eosinophilia: A systematic review and meta-analysis","volume":"14","author":"AJ Lucendo","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0270252.ref010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","article-title":"Epidemiology and clinical characteristics of GERD in the Japanese population","volume":"44","author":"Y Fujiwara","year":"2009","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref011","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1080\/07853890.2020.1782461","article-title":"Inverse time trends of peptic ulcer and reflux esophagitis show significant association with reduced prevalence of Helicobacter pylori infection","volume":"52","author":"N Yamamichi","year":"2020","journal-title":"Ann Med"},{"key":"pone.0270252.ref012","first-page":"1032","article-title":"Clinical characteristics of gastroesophageal reflux disease in Japan","volume":"56","author":"H Yamagishi","year":"2009","journal-title":"Hepatogastroenterology"},{"issue":"Suppl 15","key":"pone.0270252.ref013","first-page":"3","article-title":"Characteristics of gastroesophageal reflux disease in Japan: increased prevalence in elderly women","volume":"38","author":"K Fujimoto","year":"2003","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref014","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000489848","article-title":"Gastroesophageal reflux disease-related disorders of systemic sclerosis based on the analysis of 66 patients","volume":"98","author":"R Matsuda","year":"2018","journal-title":"Digestion"},{"key":"pone.0270252.ref015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"LR Lundell","year":"1999","journal-title":"Gut"},{"key":"pone.0270252.ref016","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1136\/gutjnl-2017-314722","article-title":"Modern diagnosis of GERD: the Lyon Consensus","volume":"67","author":"CP Gyawali","year":"2018","journal-title":"Gut"},{"key":"pone.0270252.ref017","doi-asserted-by":"crossref","first-page":"e69891","DOI":"10.1371\/journal.pone.0069891","article-title":"Background factors of reflux esophagitis and non-erosive reflux disease: a cross-sectional study of 10,837 subjects in Japan","volume":"8","author":"C Minatsuki","year":"2013","journal-title":"PLOS ONE"},{"key":"pone.0270252.ref018","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice From the American Gastroenterological Association","volume":"152","author":"DE Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0270252.ref019","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","article-title":"Proton-pump inhibitors: understanding the complications and risks","volume":"14","author":"P Malfertheiner","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0270252.ref020","doi-asserted-by":"crossref","first-page":"e56060","DOI":"10.1371\/journal.pone.0056060","article-title":"Proton pump inhibitor use in the U.S. ambulatory setting, 2002\u20132009","volume":"8","author":"SR Rotman","year":"2013","journal-title":"PLOS ONE"},{"key":"pone.0270252.ref021","doi-asserted-by":"crossref","first-page":"1756284818777943","DOI":"10.1177\/1756284818777943","article-title":"Proton-pump inhibitors among adults: a nationwide drug-utilization study","volume":"11","author":"\u00d3\u00d6 H\u00e1lfd\u00e1narson","year":"2018","journal-title":"Ther Adv Gastroenterol"},{"key":"pone.0270252.ref022","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1186\/s12913-018-3358-5","article-title":"Changes in proton pump inhibitor prescribing trend over the past decade and pharmacists\u2019 effect on prescribing practice at a tertiary hospital","volume":"18","author":"H Luo","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"pone.0270252.ref023","doi-asserted-by":"crossref","first-page":"552102","DOI":"10.3389\/fphar.2020.552102","article-title":"Use of proton pump inhibitors in Hungary: mixed-method study to reveal scale and characteristics","volume":"11","author":"M Matuz","year":"2020","journal-title":"Front Pharmacol"},{"key":"pone.0270252.ref024","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00535-011-0446-2","article-title":"Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-Tornado study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan","volume":"46","author":"T Furuta","year":"2011","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1741-7015-10-45","article-title":"Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores","volume":"10","author":"N Yamamichi","year":"2012","journal-title":"BMC Med"},{"key":"pone.0270252.ref026","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s00535-004-1417-7","article-title":"Development and evaluation of FSSG: frequency scale for the symptoms of GERD","volume":"39","author":"M Kusano","year":"2004","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref027","doi-asserted-by":"crossref","first-page":"e88277","DOI":"10.1371\/journal.pone.0088277","article-title":"Categorization of upper gastrointestinal symptoms is useful in predicting background factors and studying effects and usages of digestive drugs","volume":"9","author":"N Yamamichi","year":"2014","journal-title":"PLOS ONE"},{"key":"pone.0270252.ref028","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1442-2050.2007.00788.x","article-title":"Interobserver agreement in endoscopic evaluation of reflux esophagitis using a modified Los Angeles classification incorporating grades N and M: a validation study in a cohort of Japanese endoscopists","volume":"21","author":"H Miwa","year":"2008","journal-title":"Dis Esophagus"},{"key":"pone.0270252.ref029","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The esomeprazole Study Investigators","volume":"14","author":"PJ Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0270252.ref030","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1021\/jm300318t","article-title":"Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamin e fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB)","volume":"55","author":"Y Arikawa","year":"2012","journal-title":"J Med Chem"},{"key":"pone.0270252.ref031","article-title":"National trends in prescription proton pump inhibitor use and expenditure in the United States in 2002\u20132017","author":"AU Mishuk","year":"2020","journal-title":"J Am Pharm Assoc (2003)"},{"key":"pone.0270252.ref032","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","article-title":"Use of proton pump inhibitors in adults in France: a nationwide drug utilization study","volume":"76","author":"M Lassalle","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0270252.ref033","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000498967","article-title":"A study on the status of proton pump inhibitor prescriptions using diagnosis procedure combination data in Japan","volume":"101","author":"Y Sakata","year":"2020","journal-title":"Digestion"},{"key":"pone.0270252.ref034","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"JKY Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"pone.0270252.ref035","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.3748\/wjg.v24.i22.2373","article-title":"Treatment of Helicobacter pylori infection in atrophic gastritis","volume":"24","author":"E Lahner","year":"2018","journal-title":"World J Gastroenterol"},{"key":"pone.0270252.ref036","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00535-014-1031-2","article-title":"Time series analysis of gastric acid secretion over a 20-year period in normal Japanese men","volume":"50","author":"K Iijima","year":"2015","journal-title":"J Gastroenterol"},{"key":"pone.0270252.ref037","first-page":"CD011194","article-title":"Proton pump inhibitors for functional dyspepsia","volume":"11","author":"MI Pinto-Sanchez","year":"2017","journal-title":"Cochrane Database Syst Rev"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T17:29:32Z","timestamp":1655486972000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270252"}},"subtitle":[],"editor":[{"given":"Rasa","family":"Zarnegar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0270252","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,17]]}}}